Deb Geraghty is the founder of Anokion. Anokion has raised $160M in total funding. Latest round: Series B. Based in Zurich, Switzerland.
Deb Geraghty (Deborah Geraghty, Ph.D.) is the President and Chief Executive Officer of Anokion SA, a Swiss biotechnology company focused on treating autoimmune diseases by restoring immune tolerance. She leads the company's development of an 'inverse vaccine' platform targeting conditions such as celiac disease, multiple sclerosis, and type 1 diabetes. Geraghty was appointed to her current role in February 2021.
Full founder directory · Investor directory · Company funding database · Fundraising library